{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:08:17Z","timestamp":1715990897130},"reference-count":29,"publisher":"Informa UK Limited","issue":"12","funder":[{"name":"AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen, Novartis, Pfizer, UCB"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.2217\/imt.15.93","type":"journal-article","created":{"date-parts":[[2015,11,23]],"date-time":"2015-11-23T17:27:46Z","timestamp":1448299666000},"page":"1241-1247","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Secukinumab in The Treatment of Ankylosing Spondylitis"],"prefix":"10.1080","volume":"7","author":[{"given":"Rashmi","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Arthritis & Rheumatic Diseases,Oregon Health & Science University,\r3181 SW Sam Jackson Park Rd,\rMail Code OP-09,\rPortland,\rOR\r97239,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Perry","sequence":"additional","affiliation":[{"name":"Division of Arthritis & Rheumatic Diseases,Oregon Health & Science University,\r3181 SW Sam Jackson Park Rd,\rMail Code OP-09,\rPortland,\rOR\r97239,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis & Rheumatic Diseases,Oregon Health & Science University,\r3181 SW Sam Jackson Park Rd,\rMail Code OP-09,\rPortland,\rOR\r97239,\rUSA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2015,11,23]]},"reference":[{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.104018"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.016717"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38070"},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.021908.132710"},{"key":"e_1_3_3_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)00070-4"},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03522.x"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.2174\/187152809787582507"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C600256200"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2007.11.013"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0414-y"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24763"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1002653"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2817"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23655"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0031000"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33396"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3370"},{"key":"e_1_3_3_21_1","unstructured":"Cosentyx prescribing information . Novartis Pharmaceutical Corporation NJ USA (2015)."},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61134-4"},{"key":"e_1_3_3_23_1","volume-title":"The American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP)","author":"Deodhar A","year":"2014","unstructured":"Deodhar A , BaetenD, BranJ. Secukinumab, a monoclonal antibody to interleukin-IL17A, significantly improves physical function and quality of life in subjects with active ankylosing spondylitis: results of a Phase 3 randomized, placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Presented at : The American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP). MA, USA, 14\u201319 November 2014."},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10883"},{"key":"e_1_3_3_25_1","first-page":"862","article-title":"Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment","volume":"34","author":"Lukas C","year":"2007","unstructured":"Lukas C , BraunJ, van der HeijdeDet al. Scoring inflammatory activity of the spine by magnetic resonance imaging in ankylosing spondylitis: a multireader experiment. J. Rheumatol.34, 862\u2013870 (2007).","journal-title":"J. Rheumatol."},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3008"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3392"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.3089"},{"key":"e_1_3_3_29_1","volume-title":"The Annual Meeting of the American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP)","author":"Baeten D","year":"2014","unstructured":"Baeten D , BraunJ, BaraliakosX. Secukinumab, a monoclonal antibody to interleukin-17A, significantly improves signs and symptoms of active ankylosing spondylitis: results of a 52 week Phase 3 randomized placebo-controlled trial with intravenous loading and subcutaneous maintenance dosing. Presented at : The Annual Meeting of the American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP). MA, USA, 14\u201319 November 2014."},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-eular.2787"},{"key":"e_1_3_3_31_1","volume-title":"The Annual Meeting of the American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP)","author":"Sieper J","year":"2014","unstructured":"Sieper J , BraunJ, BaraliakosX. Secukinumab, a monoclonal antibody to interleukin-IL17A, significantly improves signs and symptoms of active ankylosing spondylitits: results of a Phase 3, randomized, placebo-controlled trial with subcutaneous loading and maintenance dosing. Presented at : The Annual Meeting of the American College of Rheumatology\/Association of Rheumatology Health Professionals (ACR\/ARHP). Boston, MA, USA, 14\u201319 November 2014."}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.15.93","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T17:21:23Z","timestamp":1715966483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.15.93"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,23]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["10.2217\/imt.15.93"],"URL":"https:\/\/doi.org\/10.2217\/imt.15.93","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-11-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}